Format

Send to

Choose Destination
Nat Rev Urol. 2009 Jul;6(7):384-91. doi: 10.1038/nrurol.2009.123.

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Author information

1
Department of Urology, University Hospital Malmö, Lund University, Sweden.

Abstract

The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate kallikreins PSA and hK2 in relation to pathology and epidemiology.

PMID:
19578355
PMCID:
PMC4455535
DOI:
10.1038/nrurol.2009.123
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center